Pacific Biosciences of California, Inc.
Financials
Valuation Metrics
Pacific Biosciences of California, Inc.'s Market Cap is $728M. At end of 2025 it was $565M. Ranked #2525 of 3,118 in US market (top 81%), #1055 of 1,474 on NASDAQ (top 72%), #160 of 203 in Health Care Equipment & Services (top 79%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $728M | US#2,525/3,118 Sec#160/203 |
| Revenue | $159M | US#2,591/3,118 Sec#173/203 |
| Net Income | $-131M | US—/3,118 Sec—/203 |
| Total Assets | $752M | US#2,592/3,118 Sec#140/203 |
| Net Assets | $-33M | US#2,933/3,118 Sec#197/203 |
| Employees | 485 | US#2,274/3,118 Sec#157/203 |
| Value | ||
| P/S | 4.57x | US#2,318/3,118 Sec#151/203 |
| FCF Yield | -23.50% | US—/3,118 Sec—/203 |
| Profitability | ||
| ROA | -17.48% | US#2,759/3,118 Sec#171/203 |
| Op. Margin | -102.05% | US#2,713/3,118 Sec#194/203 |
| Revenue Growth | 2.02% | US#2,036/3,118 Sec#153/203 |
| Financial Health | ||
| Total Debt | $706M | US#1,699/3,118 Sec#93/203 |
| FCF | $-171M | US#2,747/3,118 Sec#196/203 |
| Cash | $61M | US#2,491/3,118 Sec#157/203 |
| Current Ratio | 4.92x | US#475/3,118 Sec#39/203 |
| Performance | ||
| 1Y Return | 0.21% | US#772/3,118 Sec#71/203 |
| 1M Return | -7.68% | US#793/3,118 Sec#65/203 |
| From 52W High | -31.83% | US#1,691/3,118 Sec#133/203 |
| 1Y MDD | -58.43% | US#2,688/3,118 Sec#169/203 |
| Trading | ||
| Volume | 8,669,302 shares | US#142/3,118 Sec#4/203 |
| Trading Value | $21M | US#1,523/3,118 Sec#106/203 |
| Per Share | ||
| EPS | $-0.42 | US—/3,118 Sec—/203 |
| BPS | $-0.11 | US—/3,118 Sec—/203 |
Company Info
Pacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges. At the heart of its offerings are the proprietary PacBio Sequencing Systems, designed for executing, monitoring, and interpreting biochemical sequencing reactions. Complementing these instruments are essential consumable products, such as their unique single molecule real-time (SMRT) cells. Furthermore, the company supplies a comprehensive suite of workflow-specific reagent kits. These include template preparation kits, which utilize molecular biology reagents (like ligase, buffers, and exonucleases) to convert DNA into SMRTbell double-stranded DNA libraries. Binding kits, featuring modified DNA polymerase, facilitate the crucial attachment of SMRTbell libraries to the polymerase in readiness for sequencing. Finally, specialized sequencing kits contain all necessary reagents, including phospholinked nucleotides, for real-time sequencing directly on their instruments. Pacific Biosciences caters to a broad global clientele, encompassing prominent research institutions, commercial diagnostic laboratories, large-scale genome centers, public health organizations, hospitals, clinical research institutes, contract research organizations (CROs), academic bodies, pharmaceutical firms, and agricultural enterprises. Product commercialization is managed through a direct sales force across North America and Europe, complemented by a robust network of distribution partners spanning Asia, the Middle East, Africa, and Latin America. A significant strategic alliance includes a development and commercialization agreement with Invitae Corporation. Originally incorporated in 2000 as Nanofluidics, Inc., the company adopted its current name, Pacific Biosciences of California, Inc., in 2005. Its corporate headquarters are situated in Menlo Park, California.